BTCC / BTCC Square / Global Cryptocurrency /
Abbott Laboratories Q4 Earnings: Revenue Growth Overshadowed by Segment Weakness

Abbott Laboratories Q4 Earnings: Revenue Growth Overshadowed by Segment Weakness

Published:
2026-01-22 16:14:02
15
1
BTCCSquare news:

Abbott Laboratories reported fourth-quarter revenue of $11.46 billion, surpassing expectations, yet shares tumbled 7.35% as investors focused on softening demand in key segments. The medical device giant posted 3% organic sales growth and a 12% increase in adjusted EPS, but Nutrition and Diagnostics underperformed, dragging sentiment lower.

Medical Devices remained a bright spot, with $5.675 billion in revenue and double-digit growth across Electrophysiology, Heart Failure, and Diabetes Care. Market reaction suggests concerns over near-term headwinds outweigh solid fundamentals, as Abbott shifts focus toward 2026 growth targets.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.